Clinical evaluation of sintilimab in conjunction with bevacizumab for advanced colorectal cancer with microsatellite stable-type after failure of first-line therapy

Table 2 Pre-treatment and post-treatment positive expression rates of cluster of differentiation 8 (+) T lymphocytes, tumor-associated macrophages, and cancer-associated fibroblasts in experimental participants and controls, n (%)

Characteristic	Experimental group (n = 60)	Control group (n = 50)	P value
CD8 (+) T lymphocytes
Pre-treatment	6 (10.00)	10 (20.00)	0.139
Post-treatment	30 (50.00)	15 (30.00)	0.033
TAMs
Pre-treatment	46 (76.70)	40 (80.00)	0.673
Post-treatment	14 (23.30)	30 (60.00)	0.001
CAFs
Pre-treatment	42 (70.00)	35 (70.00)	1.000
Post-treatment	14 (23.30)	25 (50.00)	0.003

CAFs: Cancer-associated fibroblasts; CD: Cluster of differentiation; TAMs: Tumor-associated macrophages.